US OptionsDetailed Quotes
CNXC241220P55000
- 10.94
- 0.000.00%
15min DelayTrading Oct 28 12:21 ET
0.00High0.00Low
0.00Open10.94Pre Close0 Volume0 Open Interest55.00Strike Price0.00Turnover0.00%IV3.21%PremiumDec 20, 2024Expiry Date9.48Intrinsic Value100Multiplier18DDays to Expiry1.46Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.92Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Concentrix Stock Discussion
Sign in to post a comment
$XP Inc (XP.US)$ $Advanced Micro Devices (AMD.US)$ $Concentrix (CNXC.US)$ $Axcelis Technologies (ACLS.US)$ Those Stocks have positive earnings with moderate to good financial reporting. As you already missed Tech Bull in $NVIDIA (NVDA.US)$ , $Palantir (PLTR.US)$ , $Applovin (APP.US)$, you should look for potential stock that can bull like them.
Please do your own research to confirm....
Please do your own research to confirm....
+1
4
2
$Concentrix (CNXC.US)$ I am not happy with the way management is managing this company. Anyways any gain is an opportunity to extit from it. My downside target is $29. Don;t see turnaround until Q1 2025.
2
Morning Movers
Gapping up
$Micron Technology (MU.US)$ shares surged 16% after the chipmaker released current-quarter guidance that significantly exceeded analysts' expectations, driven by soaring demand for its memory chips used in artificial intelligence applications.
$Aramark (ARMK.US)$ shares climbed 5.5% after a Bloomberg report indicated that French competitor Sodexo (EPA:EXHO) is contemplating a takeover of the food cate...
Gapping up
$Micron Technology (MU.US)$ shares surged 16% after the chipmaker released current-quarter guidance that significantly exceeded analysts' expectations, driven by soaring demand for its memory chips used in artificial intelligence applications.
$Aramark (ARMK.US)$ shares climbed 5.5% after a Bloomberg report indicated that French competitor Sodexo (EPA:EXHO) is contemplating a takeover of the food cate...
Expand 18
1
9
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Concentrix (CNXC.US)$ sank more than 10% after hours Wednesday after the customer-experience-technology firm missed analyst estimates for its fiscal Q3 earnings.
CNXC fell 13.5% to $55.01 shortly before 4:45 p.m. ET after the firm said it earned $2.87 a share on a non-GAAP basis in the three months ended Aug. 31, trailing the $2.93 that published reports showed analysts' consensus forecast had called for.
The company also ra...
CNXC fell 13.5% to $55.01 shortly before 4:45 p.m. ET after the firm said it earned $2.87 a share on a non-GAAP basis in the three months ended Aug. 31, trailing the $2.93 that published reports showed analysts' consensus forecast had called for.
The company also ra...
5
1
The market fell Wednesday, but Semiconductors and software were climbing again, sending the Nasdaq higher. The S&P hit a new trading record within an hour of trading, but pulled back.
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ fell 19 basis points, the $Dow Jones Industrial Average (.DJI.US)$ fell 70, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 4 basis points.
MACRO
Wednesday, Crude Oil Inventories were cut by 4.4M bar...
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ fell 19 basis points, the $Dow Jones Industrial Average (.DJI.US)$ fell 70, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 4 basis points.
MACRO
Wednesday, Crude Oil Inventories were cut by 4.4M bar...
36
6
Analysts find Concentrix's valuation attractive but see no near-term catalysts. The impact of AI on the company remains uncertain. Despite a BUY rating from authors and analysts, Seeking Alpha's quant system rates it a STRONG SELL.
1
$Robinhood (HOOD.US)$
— Shares of the brokerage firm jumped more than 6% after unveiling its Robinhood Gold Card, a credit card where cash back can be deposited into a brokerage account.
$Concentrix (CNXC.US)$
— Shares slipped nearly 4% on the back of disappointing fiscal second-quarter earnings guidance. The customer experience technology company also reiterated its full-year outlook for 2024.
$GameStop (GME.US)$
— Shares plummeted more than 17% after th...
— Shares of the brokerage firm jumped more than 6% after unveiling its Robinhood Gold Card, a credit card where cash back can be deposited into a brokerage account.
$Concentrix (CNXC.US)$
— Shares slipped nearly 4% on the back of disappointing fiscal second-quarter earnings guidance. The customer experience technology company also reiterated its full-year outlook for 2024.
$GameStop (GME.US)$
— Shares plummeted more than 17% after th...
2
Ryan Peterson's addition to Concentrix's leadership team is expected to boost innovation and solutions. His extensive product and AI experience, especially from Amazon, is anticipated to significantly enhance the company's capabilities and product portfolio.
Concentrix's high P/E is backed by superior earnings outlook, implying potential for a future earnings drop isn't significant as per investors. This positive outlook might continue supporting the share price unless circumstances change.
1
The company's ROE is deemed respectable but not extraordinary. The significant use of debt to boost returns, leading to a lower ROE, is deemed harmful due to increased risks and reduced future options. High-quality firms manage high ROEs without significant debt.
No comment yet
72623473 : No use, internal personnel will deliberately create various troubles! Such as fire, such as leaking, and so on... Then they bottom out! Full of routines...
Steven J : I bought $Concentrix (CNXC.US)$ ,$Advanced Micro Devices (AMD.US)$ at these low levels. Sold my $Axcelis Technologies (ACLS.US)$ at 136. I like that one too. But here one of my favorite and is very undervalued $Certara (CERT.US)$ and unappreciated by wallstreet.
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. The pipeline of getting drugs approved keeps going up and Biosimulation should be beneficiary. Do your own Homework